Q32 Bio Statistics
Total Valuation
Q32 Bio has a market cap or net worth of $356.94 million. The enterprise value is $255.96 million.
| Market Cap | 356.94M |
| Enterprise Value | 255.96M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Q32 Bio has 29.77 million shares outstanding. The number of shares has increased by 21.91% in one year.
| Current Share Class | 29.77M |
| Shares Outstanding | 29.77M |
| Shares Change (YoY) | +21.91% |
| Shares Change (QoQ) | +44.32% |
| Owned by Insiders (%) | 0.71% |
| Owned by Institutions (%) | 28.05% |
| Float | 14.44M |
Valuation Ratios
The trailing PE ratio is 5.28.
| PE Ratio | 5.28 |
| Forward PE | n/a |
| PS Ratio | 6.64 |
| Forward PS | 892.34 |
| PB Ratio | 2.69 |
| P/TBV Ratio | 3.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 7.58 |
| EV / Sales | 4.76 |
| EV / EBITDA | 11.73 |
| EV / EBIT | 11.93 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.30, with a Debt / Equity ratio of 0.05.
| Current Ratio | 20.30 |
| Quick Ratio | 19.78 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.23 |
| Debt / FCF | n/a |
| Interest Coverage | 23.85 |
Financial Efficiency
Return on equity (ROE) is 72.14% and return on invested capital (ROIC) is 22.80%.
| Return on Equity (ROE) | 72.14% |
| Return on Assets (ROA) | 14.74% |
| Return on Invested Capital (ROIC) | 22.80% |
| Return on Capital Employed (ROCE) | 19.43% |
| Weighted Average Cost of Capital (WACC) | 2.33% |
| Revenue Per Employee | $2.44M |
| Profits Per Employee | $1.54M |
| Employee Count | 22 |
| Asset Turnover | 0.59 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +601.17% in the last 52 weeks. The beta is -0.38, so Q32 Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.38 |
| 52-Week Price Change | +601.17% |
| 50-Day Moving Average | 15.04 |
| 200-Day Moving Average | 8.04 |
| Relative Strength Index (RSI) | 29.11 |
| Average Volume (20 Days) | 403,497 |
Short Selling Information
The latest short interest is 3.14 million, so 10.54% of the outstanding shares have been sold short.
| Short Interest | 3.14M |
| Short Previous Month | 3.00M |
| Short % of Shares Out | 10.54% |
| Short % of Float | 21.74% |
| Short Ratio (days to cover) | 3.02 |
Income Statement
In the last 12 months, Q32 Bio had revenue of $53.74 million and earned $33.79 million in profits. Earnings per share was $2.27.
| Revenue | 53.74M |
| Gross Profit | 39.39M |
| Operating Income | 21.46M |
| Pretax Income | 33.79M |
| Net Income | 33.79M |
| EBITDA | 21.82M |
| EBIT | 21.46M |
| Earnings Per Share (EPS) | $2.27 |
Balance Sheet
The company has $106.27 million in cash and $5.30 million in debt, with a net cash position of $100.97 million or $3.39 per share.
| Cash & Cash Equivalents | 106.27M |
| Total Debt | 5.30M |
| Net Cash | 100.97M |
| Net Cash Per Share | $3.39 |
| Equity (Book Value) | 105.91M |
| Book Value Per Share | 4.46 |
| Working Capital | 104.25M |
Cash Flow
| Operating Cash Flow | -19.83M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 356,000 |
| Net Borrowing | -12.95M |
| Free Cash Flow | -19.83M |
| FCF Per Share | -$0.67 |
Margins
Gross margin is 73.30%, with operating and profit margins of 39.94% and 62.87%.
| Gross Margin | 73.30% |
| Operating Margin | 39.94% |
| Pretax Margin | 62.87% |
| Profit Margin | 62.87% |
| EBITDA Margin | 40.60% |
| EBIT Margin | 39.94% |
| FCF Margin | n/a |
Dividends & Yields
Q32 Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.91% |
| Shareholder Yield | -21.91% |
| Earnings Yield | 9.47% |
| FCF Yield | -5.56% |
Analyst Forecast
The average price target for Q32 Bio is $41.00, which is 241.95% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $41.00 |
| Price Target Difference | 241.95% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | -66.61% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Q32 Bio has an Altman Z-Score of 3.36 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.36 |
| Piotroski F-Score | 3 |